Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesLongeveron LLC

Longeveron LLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.08 USD -0.22 ( 6.67%)
Last update at 2026-11-12T15:53:00Z
VOLUME
33262
Market Cap
21.87M

Momentum Score

…

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.00
Low
3.27
High
52 Week Price Range
4.75
Low
12.30
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Longeveron develops allogeneic mesenchymal stem cell therapies, with lead candidate Lomecel‑B targeting age-related conditions including frailty and neurodegenerative disease. Long-term growth may be driven by advancement through clinical programs, collaborations to support commercialization and large demographic demand for treatments addressing aging-related disorders. Investors may find the company attractive because it appears positioned to translate a proprietary cell-therapy platform into multiple indications with significant unmet need.

Material risks include clinical or regulatory setbacks, need for external financing and dilution risk, complex manufacturing and scale-up hurdles, and competition from larger biotechnology firms.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.30
Dividend Yield
-
Revenue TTM
1.19M
Revenue Per Share
0.49
Gross Profit TTM
0.83M
Debt / Equity
0.15
ROE
-203.61%
Net Debt
-3.84M
ROCE
-367.74%
Diluted EPS TTM
-10.00

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -22.70M -15.97M -21.41M -18.84M -17.05M
Net income -22.70M -15.97M -21.41M -19.63M -17.16M
Selling general administrative 12.05M 9.47M 12.18M 8.12M 10.73M
Selling and marketing expenses - 0.80M 0.78M 1.05M 0.22M
Gross profit 0.80M 1.88M 0.22M 0.50M 0.59M
Reconciled depreciation 1.23M 0.96M 0.95M 0.89M 0.91M
Ebit -22.70M -15.97M -21.41M -18.04M -17.46M
Ebitda -21.48M -15.02M -20.47M -17.44M -16.43M
Depreciation and amortization 1.23M 0.96M 0.95M 0.61M 1.03M
Non operating income net other - - - -0.79M 0.41M
Operating income -23.29M -16.52M -21.03M -18.04M -17.46M
Other operating expenses 24.49M 18.91M 21.74M 19.27M 18.76M
Interest expense - - - -0.29M 0.00M
Net interest income - - - 0.00M -0.00M
Income tax expense - -24.62M 0.78M 0.79M 0.12M
Total revenue 1.20M 2.39M 0.71M 1.22M 1.31M
Total operating expenses 24.09M 18.41M 21.25M 18.54M 18.05M
Cost of revenue 0.40M 0.51M 0.49M 0.72M 0.72M
Total other income expense net 0.58M 0.55M -0.38M -0.79M 0.41M
Net income from continuing ops -22.70M -15.97M -19.84M -18.84M -17.05M
Net income applicable to common shares - - - -18.84M -17.05M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 10.26M 25.56M 12.18M 27.41M 42.77M
Intangible assets 2.29M 2.40M 2.29M 2.41M 2.33M
Other current assets 0.69M 0.31M 0.38M 0.40M 0.28M
Total liab 4.59M 3.67M 5.34M 6.91M 5.31M
Total stockholder equity 5.67M 21.89M 6.84M 20.50M 37.45M
Other current liab 2.97M 1.82M 2.15M 2.05M 1.33M
Common stock 0.02M 0.01M 0.03M 0.02M 0.02M
Capital stock 0.02M 0.01M 0.03M 0.02M 0.02M
Retained earnings -132.31M -109.61M -84.98M -62.77M -43.94M
Other liab - - - - 5.31M
Other assets - - - 0.24M 2.33M
Cash 4.66M 19.23M 4.95M 10.50M 25.66M
Total current liabilities 4.09M 2.58M 3.89M 4.87M 2.71M
Current deferred revenue 0.04M 0.04M 0.51M 0.51M 0.20M
Net debt -3.84M -17.79M -2.91M -7.90M -22.52M
Short term debt 0.66M 0.62M 0.59M 0.56M 0.54M
Short long term debt total 0.82M 1.45M 2.04M 2.60M 3.14M
Other stockholder equity 137.96M 131.48M 91.80M 83.61M 81.37M
Property plant equipment - - - 2.95M 3.06M
Total current assets 5.45M 19.62M 5.85M 19.66M 35.38M
Net tangible assets - - - 18.09M 35.12M
Short term investments - 0.00M 0.41M 9.15M 9.38M
Net receivables 0.10M 0.08M 0.11M 0.22M 0.06M
Long term debt - - - 2.04M 2.60M
Inventory - - - -0.62M 0.28M
Accounts payable 0.42M 0.10M 0.64M 1.75M 0.65M
Accumulated other comprehensive income - - -0.10M -0.36M -
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -62.77M -43.94M
Treasury stock - - - -0.10M -0.10M
Non currrent assets other 0.08M 0.20M 0.09M 2.40M 0.18M
Non current assets total 4.81M 5.93M 6.33M 7.75M 7.39M
Capital lease obligations 0.82M 1.45M 2.04M 2.60M 3.14M
Long term debt total - - - 2.04M 2.60M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M -0.64M 6.05M -0.68M -9.47M
Change to liabilities - - - 0.43M -1.16M
Total cashflows from investing activities -0.59M -0.64M 8.19M -0.68M -10.70M
Net borrowings - - - - -0.19M
Total cash from financing activities 4.67M 28.79M 5.26M -0.51M 45.17M
Change to operating activities - - - -1.01M -0.70M
Net income -22.70M -15.97M -21.41M -18.84M -17.05M
Change in cash -14.57M 14.28M -5.55M -15.15M 24.84M
Begin period cash flow 19.23M 4.95M 10.50M 25.66M 0.82M
End period cash flow 4.66M 19.23M 4.95M 10.50M 25.66M
Total cash from operating activities -18.64M -13.87M -19.00M -13.97M -9.64M
Issuance of capital stock 4.98M 12.87M 5.34M 0.00M 45.19M
Depreciation 1.23M 0.96M 0.95M 0.89M 0.91M
Other cashflows from investing activities - -0.99M 8.49M -0.11M -0.90M
Dividends paid - 8.65M - - -
Change to account receivables -0.02M 0.03M 0.11M -0.16M 0.37M
Sale purchase of stock - - -0.17M 0.00M 45.81M
Other cashflows from financing activities -0.31M 24.57M 5.44M -0.51M 0.17M
Change to netincome - - - 2.64M 8.01M
Capital expenditures 0.24M 0.99M 0.30M 0.86M 1.31M
Change receivables - - - -0.16M 0.37M
Cash flows other operating - - - 1.06M -0.72M
Cash and cash equivalents changes - - - -15.15M 24.84M
Change in working capital 1.06M -1.24M 0.04M 0.24M -1.09M
Stock based compensation 1.68M 2.33M 2.03M 2.34M 7.74M
Other non cash items 0.10M 0.06M -0.60M 1.40M -0.15M
Free cash flow -18.89M -14.86M -19.30M -14.82M -10.95M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LGVN
Longeveron LLC		 -0.22
6.67%		 3.08 - - 18.43 2.13 10.67 -49.61
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Longeveron LLC

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Life Science & Technology Park, Miami, FL, United States, 33136

844 470 2550

https://longeveron.com

38

Name Title Year Born
Dr. Joshua Michael Hare FACC, M.D. Co-Founder, Chief Science Officer & Chairman 1963
Mr. James Clavijo CPA CFO & Treasurer 1966
Mr. Paul T. Lehr J.D. International Exec. Director, Gen. Counsel & Sec. 1968
Dr. Kwan-Hong Min M.D., Ph.D. Chief Medical Officer & Interim CEO 1967
Dr. Dan Gincel Ph.D. Sr. VP of Strategic Collaborations & Scientific Affairs 1971
Mr. Mohamed Wa'el Ahmed Hashad CEO & Director 1962
Ms. Lisa A. Locklear M.B.A. Executive VP & CFO 1962
Mr. Paul T. Lehr J.D. International Executive Director, General Counsel & Secretary 1968
Dr. Dan Gincel Ph.D. Senior Vice President of Strategic Collaborations & Scientific Affairs 1971
Dr. Nataliya Agafanova M.D. Chief Medical Officer 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…